We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nucleic Acid Preparations Identify Norovirus and Mycoplasma pneumonia

By LabMedica International staff writers
Posted on 15 Oct 2013
Image:  DiaSorin's LIAISON IXT for the purification of nucleic acids (Photo courtesy of Diasorin).
Image: DiaSorin's LIAISON IXT for the purification of nucleic acids (Photo courtesy of Diasorin).
Extraction kits provide high yield, high purity nucleic acid preparations for sensitive and accurate molecular identification of Norovirus and Mycoplasma pneumonia.

Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.

The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.

Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.

Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.

During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.

DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.

In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.

Related Links:
DiaSorin

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Automated Clinical Chemistry Analyzer
Envoy 500+

Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more